Asieris Pharmaceuticals Gets 700 Mliion Yuan in Series D

Asieris Pharmaceuticals, a global innovative drug research and development company focusing on anti-tumor and related diseases of the genitourinary system, announced the completion of Series D financing. It is reported that this round of financing was led by Qiming Venture Capital, with Yunfeng Fund, CICC Capital's CICC Fund and Yicun Capital participating in the investment, and the total transaction amount exceeded 700 million yuan.

The funds raised in this round will be used to support the development of the company's existing pipeline products, the construction of technology platforms, and to accelerate commercialization and industrialization.

Asieris Pharmaceuticals, founded in March 2010 in China Medical City in Jiangsu Taizhou, is the only China-based, globally oriented company specializing in the R&D of new drugs for the treatment of genitourinary tumors and related diseases. 

Asieris Pharmaceuticals focuses on the development of novel anti-cancer and anti-multidrug resistance infection drugs with high market potentials and unmet needs in the clinical through internal research and collaboration. Meanwhile, we leverage our leading position in the field of urological oncology to selectively in-license products from foreign companies for co-developing the market in China.

Professional teams of Asieris are located in Shanghai, Beijing, and Taizhou (Jiangsu), as well as in the United States, with departments responsible for domestic and international clinical development, regulatory affairs, pharmaceutical sciences, new drug discovery, and business development. 

With focus on genitourinary tumors and related diseases, the company’s goal is to establish a leading position in this field with our own unique strategies. Through the “twin engines” of proprietary R&D and in-licensing, Asieris explore the global values of proprietary first-in-class new drugs of breakthrough potential. Meanwhile, we in-license late stage or marketed new drugs from overseas for the Chinese market to enhance product pipeline and allow us to quickly establish leadership position in the domestic market.

Asieris Pharmaceuticals focuses on the development of novel anti-cancer and anti-multidrug resistance infection drugs with high market potentials and unmet needs in the clinical through internal research and collaboration. Meanwhile, we leverage our leading position in the field of urological oncology to selectively in-license products from foreign companies for co-developing the market in China.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and San Francisco Bay Area. Currently Qiming Venture Partners manages nine US Dollar funds and five RMB funds with $5.6 billion assets under management. Since our establishment, we have invested in outstanding companies in the TMT and healthcare industries at the early and growing stages.

Qiming Venture Partners is a top-tier VC firm with outstanding reputation. Qiming has been widely recognized by investors from around the world and has become an ideal VC firm for entrepreneurs. With our exceptional investment performances, Qiming has won multiple world-renowned venture capital awards.